Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding.

"This is a good opportunity for Omeros and represents a potential life-saving treatment for patients. With the withdrawal of Trasylol® from the market in 2008, there is an immediate need for a safe and effective antifibrinolytic," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The ex vivo human and in vivo animal efficacy data look strong, and the regulatory pathway is well-defined. We have begun IND-enabling activities and are working to advance the program quickly to the clinic."

Excessive bleeding during cardiac surgery is known to increase overall morbidity and mortality. In an attempt to control this bleeding, patients undergoing cardiac and other extensive surgery often receive antifibrinolytic compounds. Until its permanent withdrawal from the market in 2008, the antifibrinolytic Trasylol® (aprotinin) had been shown in a number of studies to be more effective at reducing blood loss than the other two commonly used agents, tranexamic acid (TXA) and epsilon aminocaproic acid (EACA). Though effective, Trasylol® had a number of limitations. It was a bovine protein that was associated with anaphylactic reactions. Further, Trasylol® was non-selective and inhibited many proteins in addition to plasmin, including Factor XIa and kallikrein, important regulators of the coagulation cascade. Trasylol® was permanently withdrawn from the market after its use was found to be associated with increased mortality. While the specific cause of this increase remains unknown, an often-cite
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 On September ... sole exhibition focusing on medical design and manufacturing - ... the Shanghai World Expo Exhibition & Convention Center, bringing ... countries and regions to showcase their latest medical-grade raw ... now only one week remaining for free visitor pre-registration ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
... ImpactRx, the pioneer in measuring the impact ... Kjell Nygren, Ph.D. has joined the company as ... company,s position as a state-of-the-art provider of analytical ... the effectiveness of their promotional activities in driving ...
Cached Medicine Technology:New Test to Screen for Glaucoma Damage 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
(Date:9/16/2014)... Lake Worth, FL (PRWEB) September 16, 2014 ... Millennium Treatment Group, they take care to make sure ... best for them. For some, this may include the ... new online therapy program which gives patients the opportunity ... Millennium Treatment Group can provide medical and clinical care ...
(Date:9/16/2014)... September 16, 2014 Aspen Advisors, a ... has been recognized for its high morale and ... “The Best Small Firms to Work For 2014.” ... with more than 10,000 consultants participating across all major ... satisfaction surveys were conducted, and firms were ranked in ...
(Date:9/16/2014)... cancer may one day be able to predict when ... and sexual functioning, thanks in part to new findings ... the American Society for Radiation Oncology,s 56th Annual Meeting ... from more than 17,000 surveys completed by men diagnosed ... urinary and sexual symptoms changed following each type of ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in ... hypertension association that works to find ways to prevent and ... that affects the functioning of the heart and can lead ... 2.8 years. , What:, Colorado PH in the Park ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News: Most Treatments for Blood Clots Appear Safe, Effective 2
... 3, 2008 A new study presented ... by researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) ... Vitamin C with,Bioperine(R), provides 275 percent faster ... Reece, President of Scientific Food Solutions said, ...
... the American Association for Dental Research,s (AADR) High School ... with the AADR,s 37th Annual Meeting & Exhibition at ... the High School for Health Professions, the Talented and ... School. The program includes a tour of Baylor College ...
... how to eat during seasons key to maintaining health, ... get bombarded on a,regular basis about health, diets and ... According to the Institute for Integrative Nutrition,the largest nutrition ... to maintaining health and wellness, regardless of which,diet you ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration and ... novel thermal energy called plasma for reversing the ... Food and Drug Administration (FDA),clearance to market a ... already cleared by the FDA for treating facial ...
... Campos Ramirez, 60, was sentenced to 10 years in ... defraud Medicare, Assistant Attorney General,Alice S. Fisher of the ... Southern District of Florida announced today. The scheme,represents the ... of the program., Campos was sentenced today in ...
... Ventas, Inc.,(NYSE: VTR ) ("Ventas" or the ... the Company at the Credit Suisse 2008 Global,Real Estate ... at 2:50 p.m.,Eastern Time., The presentation will be ... http://www.ventasreit.com . Any written materials,accompanying the presentation will ...
Cached Medicine News:Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Owner of Medicare Billing Service Sentenced to 10 Years In Prison For Role in $170 Million Medicare Fraud Scheme 2
... Blood Pressure Monitoring System extends the ... by providing continuous, real-time derivation of ... parameters are sampled every 5 seconds, ... Central Systolic, Diastolic, and Pulse Pressures ...
... BD Xstar Blade includes a specially designed, ... in prodedure and handling. The Xstar ... process for manufacturing surgical blades. This ... The arch style, single-bevel geometry allows ...
Electric high speed system....
Compressor-cooled plate used to keep blocks cold while sectioning....
Medicine Products: